Stock Markets March 25, 2026

Bunge Shares Slip After Short Seller Demands Independent Probe of Financial Reporting

Spruce Point's forensic review alleges long-term cash-flow deficits, debt-funded payouts and questions around core oilseeds business and recent Viterra deal

By Hana Yamamoto BG
Bunge Shares Slip After Short Seller Demands Independent Probe of Financial Reporting
BG

Shares of Bunge Global SA declined more than 2% in pre-market trading after short seller Spruce Point Management published a forensic review calling for an independent investigation into the agribusiness's accounting and financial disclosures. The report alleges a long history of cash-flow shortfalls after investments, sizable dividend and buyback programs funded by debt, and structural pressure in the oilseeds business. Spruce Point also criticizes Bunge's $10.6 billion acquisition of Viterra and notes the company has not publicly addressed the potential impact of GLP-1 weight loss drugs on its food-industry customers.

Key Points

  • Shares of Bunge declined more than 2% in pre-market trading after Spruce Point published a forensic review calling for an independent investigation.
  • Spruce Point alleges a cumulative $1.6 billion cash-flow deficit since 1999 after investments, while dividends and buybacks totaled $4.7 billion and $3.9 billion respectively, financed by debt.
  • The short seller flags pressure in Bunge's oilseeds business, criticism of the $10.6 billion Viterra acquisition, and a lack of discussion in filings about GLP-1 drugs' potential impact on food customers.

Shares of Bunge Global SA fell by more than 2% shortly before the market opened on Wednesday after short seller Spruce Point Management released a detailed forensic review calling for an independent investigation into the company's financial reporting and accounting practices.

In its report, Spruce Point describes the S&P 500-listed agribusiness as a complex roll-up that the short seller says has struggled to produce shareholder value without resorting to outside financing. The review sets out a series of financial assertions and strategic criticisms aimed squarely at Bunge's capital allocation and disclosures.

Among the report's specific claims, Spruce Point asserts that since 1999 Bunge has produced a cumulative cash flow deficit of $1.6 billion after accounting for capital expenditures, business investment and asset repositioning. During that same period, the short seller says the company distributed $4.7 billion in dividends and repurchased $3.9 billion of stock, actions the report contends were financed through additional debt.

Spruce Point singles out Bunge's oilseeds segment - historically its largest contributor to EBIT - as an area under mounting pressure. The short seller also notes that Bunge has not, according to its analysis, addressed the growing influence of GLP-1 weight loss drugs in its Securities and Exchange Commission filings or in public conference calls, despite the company serving customers in the packaged food sector.

Based on its review, Spruce Point estimates a potential downside range for Bunge shares of 55% to 80% and warns of material market underperformance risk. The report characterizes Bunge's $10.6 billion acquisition of Viterra from Glencore, announced in June 2023, as a transaction driven by necessity rather than strategic opportunity, and labels the deal as having substantially disappointed relative to expectations.

The short seller urged Bunge's board to open an investigation into matters related to the company's financial reporting and to provide greater clarity to investors. The report also raises concerns about new 2030 EPS guidance and signals the possibility of significant insider selling, warning that up to 30% of shares could be sold in the near term.

Bunge Global SA is incorporated in Geneva, Switzerland and is headquartered in St. Louis, Missouri. The company is an international exporter of soybeans and operates across food processing, grain trading and fertilizer businesses. Bunge shares have risen roughly 70% over the past 12 months, a performance figure noted in the report.


Context and next steps

Market reaction to the Spruce Point document was immediate, with the stock trading lower in pre-market activity. The short seller's demands for an independent probe, coupled with its financial calculations and strategic critique, present a direct challenge to management to address the allegations publicly and to clarify the assumptions behind its guidance and recent acquisitions.

At present, the report outlines its concerns and requests but does not itself change any filed financial statements or announced transactions. How Bunge responds, and whether its board will authorize the type of independent review Spruce Point seeks, remains to be seen.

Risks

  • Potential for material downside in Bunge shares - Spruce Point estimates a 55% to 80% decline and warns of market underperformance risk, affecting equity investors and agribusiness sector sentiment.
  • Uncertainty around financial reporting and accounting practices - calls for an independent investigation create governance and disclosure risk for Bunge and may prompt scrutiny from investors and the board.
  • Strategic and operational pressures in oilseeds and integration risk from the Viterra acquisition - these concerns may affect supply-chain participants, grain trading, and packaged food customers.

More from Stock Markets

Broadcom to Build Google’s Next-Gen AI Chips Under Long-Term Pact; Anthropic Gains Access to Multi-Gigawatt Capacity Apr 6, 2026 OpenAI Asks California and Delaware Attorneys General to Probe Alleged Anti-Competitive Conduct by Elon Musk and Associates Apr 6, 2026 Broadcom Secures Multi-Year TPU and Networking Supply Deals with Google; Shares Rise After-Hours Apr 6, 2026 Mexican Equities Slip as Major Sectors Drag Index Down 1.03% Apr 6, 2026 Colombian equities finish higher as COLCAP reaches one-month peak Apr 6, 2026